PDCD1 and cancer: Breaking immune tolerance by therapeutic PD-1 blockade has been demonstrated to represent a therapeutic breakthrough and show broadly efficacious and durable cancer immunotherapies [41-44] as well as therapeutic potential in chronic viral infection [45].